KYMR — Kymera Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual balance sheet for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	92	296	442	407	375
Net Total Accounts Receivable
Net Total Receivables	0	1.43	0.135	2.54	18.8
Prepaid Expenses
Total Current Assets	92.8	302	451	419	405
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	22.1	20.7	21.3	22.2	101
Long Term Investments
Other Long Term Assets
Total Assets	117	487	606	603	576
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	34.6	111	92.5	71.3	85.7
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	82	203	146	113	181
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	34.7	284	460	490	395
Total Liabilities & Shareholders' Equity	117	487	606	603	576
Total Common Shares Outstanding